KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables (2020 - 2025)

Historic Receivables for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $71.2 million.

  • AbCellera Biologics' Receivables rose 12709.97% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.2 million, marking a year-over-year increase of 12709.97%. This contributed to the annual value of $33.6 million for FY2024, which is 989.21% up from last year.
  • Per AbCellera Biologics' latest filing, its Receivables stood at $71.2 million for Q3 2025, which was up 12709.97% from $70.0 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Receivables high stood at $334.4 million for Q1 2022, and its period low was $20.0 million during Q1 2023.
  • In the last 5 years, AbCellera Biologics' Receivables had a median value of $45.7 million in 2023 and averaged $78.5 million.
  • Per our database at Business Quant, AbCellera Biologics' Receivables skyrocketed by 14285.29% in 2022 and then plummeted by 9401.83% in 2023.
  • Quarter analysis of 5 years shows AbCellera Biologics' Receivables stood at $160.6 million in 2021, then plummeted by 75.97% to $38.6 million in 2022, then fell by 20.74% to $30.6 million in 2023, then rose by 9.89% to $33.6 million in 2024, then soared by 111.95% to $71.2 million in 2025.
  • Its last three reported values are $71.2 million in Q3 2025, $70.0 million for Q2 2025, and $63.6 million during Q1 2025.